Fosun Pharma (02196) Achieves Overseas Equity License for Small Molecule Innovative Drug XH-S004, with a Potential Total Value of $645 million US dollars.

According to the Zhixin Financial APP, on August 11th, Fosun Pharmaceutical (600196.SH, 02196) announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharmaceutical Industry"), has signed a "License Agreement" with Expedition Therapeutics, Inc. ("Expedition"), granting Expedition the global (excluding China and Hong Kong/Macau) rights to develop, produce, and commercialize the small molecule orally available dipeptidyl peptidase-1 (DPP-1) inhibitor XH-S004. Fosun Pharmaceutical Industry will retain the rights to develop, produce, and commercialize XH-S004 in China and Hong Kong/Macau.